4//SEC Filing
Protea Biosciences Group, Inc. 4
Accession 0001144204-14-065252
CIK 0001335103operating
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 2:43 PM ET
Size
10.6 KB
Accession
0001144204-14-065252
Insider Transaction Report
Form 4
SEGAL SCOTT
Director
Transactions
- Conversion
Series A Convertible Preferred Stock
2014-10-31+52,319→ 52,319 total→ Common Stock (418,552 underlying) - Conversion
Convertible Note
2014-10-31From: 2014-10-31Exp: 2014-10-31→ Series A Preferred Convertible Stock & Warrants - Conversion
Warrant
2014-10-31+209,276→ 1,502,624 totalExercise: $0.38From: 2014-10-31Exp: 2017-10-31→ Common Stock (209,276 underlying)
Footnotes (2)
- [F1]The Issuer issued Series A Convertible Preferred Stock (the "Preferred Stock") in connection with the conversion of $104,639 outstanding principal and accrued unpaid interest of a certain covertible promissory note (the "Note") to Scott Segal (the "Reporting Person"). Each share of Preferred Stock has a stated value equal to $2.00, subject to increase based on the accrual of a 6% dividend (the "Stated Value"). The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the Stated Value by $0.25 per share on February 17, 2015, subject to extension.
- [F2]In connection with th conversion of the Note, the Reporting Person also received a 3 year warrant to purchase up to 209,276 shares of the Company's common stock, exercisable at $0.375 per share.
Documents
Issuer
Protea Biosciences Group, Inc.
CIK 0001335103
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001335103
Filing Metadata
- Form type
- 4
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 2:43 PM ET
- Size
- 10.6 KB